ALK's Needle-Free Adrenaline Approval Shakes Up Pediatric Allergy Market

LONDON, UK – June 15, 2026 – Danish pharmaceutical firm ALK has secured a pivotal UK regulatory approval for a product that could fundamentally reshape the multi-million-pound market for emergency allergy treatment. The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for EURneffy® 1 mg, a nasal spray designed to treat severe allergic reactions, or anaphylaxis, in young children.

This approval is not just another line extension; it marks the arrival of the first and only needle-free adrenaline treatment for children aged four and older (weighing 15-30 kg) in the United Kingdom. For decades, the standard of care has been adrenaline auto-injectors (AAIs)—devices like the EpiPen that, while effective, come with a significant barrier: the needle. By replacing the injection with a simple nasal spray, ALK is betting that it can solve a deeply entrenched problem of patient fear and user error, unlocking significant market share in the process.

A Calculated Disruption in a Stable Market

The market for anaphylaxis treatment has long been dominated by established AAI brands, including Viatris's EpiPen and, ironically, ALK's own Jext injector. By introducing EURneffy, ALK is making a strategic play to disrupt not only its competitors but its own existing product line. This move signals a clear bet on innovation as the primary driver of growth, aiming to expand the overall market by converting non-compliant or hesitant users into active ones.

The business case is compelling. ALK’s anaphylaxis segment already reported a staggering 58% year-over-year growth in 2025, even before this pediatric approval. The introduction of EURneffy for adults and heavier children in late 2025 laid the groundwork, and this new 1 mg dose for younger children targets one of the most anxious and underserved demographics. The product itself, known as neffy® in the United States, was developed by the US-based ARS Pharmaceuticals, with ALK securing exclusive commercialization rights for Europe and other key territories. This licensing strategy allowed ALK to bring a market-ready innovation into its portfolio without bearing the full R&D timeline and cost, a shrewd move that accelerates its competitive assault.

Industry analysts see this as a classic disruptive strategy. Instead of competing on price or incremental features, ALK is changing the user experience entirely. Anaphylaxis affects up to 761 per 100,000 children in Europe annually, with food allergies being the primary trigger. For the parents and caregivers of these children, the fear of using an injector correctly and forcefully on a small child during a high-stress emergency is a major deterrent. EURneffy's pocket-sized, pre-primed nasal spray is designed to be as intuitive as a common decongestant, a powerful unique selling proposition.

Solving the Human Factor: From Fear to Compliance

The true bottom-line impact of EURneffy lies in its ability to solve a human problem that has long plagued anaphylaxis management. Data presented at the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Congress revealed that nearly 40% of adults at risk of anaphylaxis do not regularly carry their AAI, with fear of needles cited as a key reason. For children, this problem is magnified.

“For years, the fear of the needle has been a secondary trauma alongside the allergy itself,” a representative from a leading UK anaphylaxis charity noted. “An option that removes this barrier is not just a convenience; it’s a lifeline that could dramatically increase the odds of timely treatment.”

ALK is directly targeting this compliance gap. Flora Beiche-Scholz, EVP of Commercial Operations for Europe at ALK, stated, “For decades, children at risk of anaphylaxis have been limited to injectable adrenaline – yet fear of needles, hesitancy to act and incorrect administration mean adrenaline is too often not carried or used in time. EURneffy® 1 mg aims to address these barriers.”

By increasing the likelihood that a caregiver will carry and, crucially, use the device, ALK’s innovation translates directly into better health outcomes. Prompt adrenaline administration is the single most important factor in preventing fatalities from anaphylaxis. Fewer delays mean fewer severe outcomes, reduced hospitalizations, and a lower overall burden on the healthcare system—a powerful value proposition when negotiating with payors like the NHS.

The Path to Clinical and Commercial Success

MHRA approval was granted based on a robust clinical development program involving over 700 participants. Studies demonstrated that EURneffy provides rapid absorption of adrenaline, with a pharmacokinetic and pharmacodynamic effect comparable to that of traditional injections. The safety profile is well-established; the most common adverse reactions in the pediatric group were mild and transient, including nasal congestion and dryness.

With regulatory approval secured, the next hurdle is commercial integration. The 2 mg dose for adults, approved in July 2025, became available on the NHS in the third quarter of that year, setting a positive precedent. ALK will now engage with the National Institute for Health and Care Excellence (NICE) to demonstrate the cost-effectiveness of the 1 mg dose. The argument will likely center on the total value of improved compliance and better patient outcomes, not just the unit price of the device.

The product's design features—a 24-month shelf life without special refrigeration and a single-use, no-prime mechanism—also offer practical advantages for both patients and pharmacy supply chains, further strengthening its case for adoption.

This UK approval is part of a coordinated global rollout. Under the brand name neffy®, the product has already been approved and launched in the United States, Japan, and Australia, with other major markets like Canada on the horizon. This demonstrates ALK's ambition to establish a new global standard in emergency anaphylaxis care. For a company historically rooted in allergy immunotherapy, this aggressive push into the acute treatment space diversifies its revenue and solidifies its position as a comprehensive leader in the allergy field. The success of EURneffy will likely force competitors to accelerate their own R&D into alternative delivery systems, heralding a new era of innovation in emergency medicine where patient-centric design is paramount.